J Korean Med Sci.  2014 Mar;29(3):416-422. 10.3346/jkms.2014.29.3.416.

Prophylactic Effect of Erythropoietin Injection to Prevent Acute Mountain Sickness: An Open-Label Randomized Controlled Trial

• Heo K
• Kang JK
• Choi CM
• Lee MS
• Noh KW
• Kim SB

• KMID: 1734931
• DOI: http://doi.org/10.3346/jkms.2014.29.3.416

Abstract

This study was performed to evaluate whether increasing hemoglobin before ascent by prophylactic erythropoietin injections prevents acute mountain sickness (AMS). This open-label, randomized, controlled trial involved 39 healthy volunteers with hemoglobin < or =15.5 g/dL who were divided randomly into erythropoietin (n=20) and control (n=19) groups. Epoetin alpha 10,000 IU injections were given weekly for four consecutive weeks. On day 1, and 7 days after the last injection (day 29), oxygen saturation (SaO2), and hemoglobin were measured. The subjects departed Seoul on day 30 and arrived at Annapurna base camp (ABC, 4,130 m) on day 34. AMS was diagnosed when headache and Lake Louise score (LLS) of > or =3 were present. Immediate descent criteria followed US Army recommendations. Two groups differ in hemoglobin levels on day 29 (15.4+/-1.1 vs 14.2+/-1.0 g/dL, P=0.001). At ABC, erythropoietin group had a significantly lower mean LLS, AMS incidence, and number of subjects who met immediate descent criteria. Multiple logistic regression analysis showed that SaO2<87% and control group, but not hemoglobin<15.0 g/dL, independently predicted satisfaction of immediate descent criteria. Erythropoietin-related adverse effects were not observed. In conclusion, erythropoietin may be an effective prophylaxis for AMS.(Clinical Trial Registry Number; NCT 01665781).

Keyword

Erythropoietin; Acute Mountain Sickness; Hemoglobins; Arterial Oxygen Saturation

MeSH Terms

Acute Disease
Adult
Altitude Sickness/diagnosis/epidemiology/*prevention & control
Blood Pressure/physiology
Drug Administration Schedule
Erythropoietin/*therapeutic use
Female
Headache/physiopathology
Hemoglobins/analysis
Humans
Incidence
Logistic Models
Male
Middle Aged
Odds Ratio
Oxygen/blood
Questionnaires
Recombinant Proteins/therapeutic use
Erythropoietin
Hemoglobins
Oxygen
Recombinant Proteins

Reference

1. Roach RC, Bärtsch P, Oelz O, Hackett PH. the Lake Louise Consensus Committee. The lake louise acute mountain sickness scoring system. In : Sutton JR, Houston CS, Coates G, editors. Hypoxia and molecular medicine. Burlington: Queen City Printers;1993. p. 272–274.

2. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001; 345:107–114.

3. Milledge JS, Cotes PM. Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol. 1985; 59:360–364.

4. Lundby C, Olsen NV. Effects of recombinant human erythropoietin in normal humans. J Physiol. 2011; 589:1265–1271.

5. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care. 2004; 8:337–341.

6. Miskowiak K, Inkster B, O'Sullivan U, Selvaraj S, Goodwin GM, Harmer CJ. Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res. 2008; 184:313–321.

7. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, Cowen PJ, Harmer CJ. Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study. Psychopharmacology (Berl). 2009; 207:133–142.

8. Rasmussen P, Kim YS, Krogh-Madsen R, Lundby C, Olsen NV, Secher NH, van Lieshout JJ. Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans. FASEB J. 2012; 26:1343–1348.

9. U.S. Army Research Institute of Environmental Medicine. Altitude acclimatization and illness management: Technical Bulletin Medical 505, 2010. accessed on 22 May 2012. Available at http://www.usariem.army.mil/assets/docs/partnering/TB-Med-505-Sept-2010.pdf.

10. Villafuerte FC, Cárdenas R, Monge-C C. Optimal hemoglobin concentration and high altitude: a theoretical approach for Andean men at rest. J Appl Physiol (1985). 2004; 96:1581–1588.

11. Park JS, Kim SB, Park SK, Lim TH, Lee DK, Hong CD. Effect of recombinant human erythropoietin on muscle energy metabolism in patients with end-stage renal disease: a 31P-nuclear magnetic resonance spectroscopic study. Am J Kidney Dis. 1993; 21:612–618.

12. Park JS, Kim SB, Park SK, Lim TW, Lee DK, Hong CD. Effects of RBC transfusion on muscle energy metabolism measured by 31P-NMR spectroscopy in patients with end stage renal disease [Abstract]. J Am Soc Nephrol. 1992; 3:429.

13. Connes P, Perrey S, Varray A, Préfaut C, Caillaud C. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch. 2003; 447:231–238.

14. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, Martin DT, Trout GJ, Hahn AG. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica. 2000; 85:564–572.

15. Wilkerson DP, Rittweger J, Berger NJ, Naish PF, Jones AM. Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans. J Physiol. 2005; 568:639–652.

16. Krzyzanski W, Perez-Ruixo JJ. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res. 2007; 24:758–772.

17. Roach RC, Greene ER, Schoene RB, Hackett PH. Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med. 1998; 69:1182–1185.

18. Luks AM, Swenson ER. Pulse oximetry at high altitude. High Alt Med Biol. 2011; 12:109–119.

19. Lundby C, Damsgaard R. Exercise performance in hypoxia after novel erythropoiesis stimulating protein treatment. Scand J Med Sci Sports. 2006; 16:35–40.

20. Robach P, Calbet JA, Thomsen JJ, Boushel R, Mollard P, Rasmussen P, Lundby C. The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia. PLoS One. 2008; 3:e2996.

21. Clarke C. Acute mountain sickness: medical problems associated with acute and subacute exposure to hypobaric hypoxia. Postgrad Med J. 2006; 82:748–753.

22. Kelly TE, Hackett PH. Acetazolamide and sulfonamide allergy: a not so simple story. High Alt Med Biol. 2010; 11:319–323.

23. Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, Zafren K, Hackett PH. Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med. 2010; 21:146–155.

24. American Society of Health-System Pharmacists. AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists;2010.